<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029430</url>
  </required_header>
  <id_info>
    <org_study_id>ALDOXORUBICIN-P2-KS-01</org_study_id>
    <nct_id>NCT02029430</nct_id>
  </id_info>
  <brief_title>A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma</brief_title>
  <official_title>An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV
      positive subjects with Kaposi's sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label pilot phase 2 study to investigate efficacy, safety, and intratumoral
      kinetics of aldoxorubicin in HIV-Infected patients with Kaposi's sarcoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To evaluate the uptake of aldoxorubicin into the tumor and the objective response rate (complete and partial response) using RECIST 1.1 criteria in subjects with HIV-infected with Kaposi's sarcoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To evaluate the safety of ALDOXORUBICIN in this population, assessed by the frequency and severity of adverse events (AEs), abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram (ECHO) evaluations, electrocardiogram (ECG) results, and weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To evaluate the intratumoral kinetics of ALDOXORUBICIN and related biomarker expression through sequential biopsies of KS skin lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To determine the change in performance status (PS) as measured by the Karnofsky Performance Status (KPS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the change in quality of life as measured by the KS Functional Assessment of HIV (FAHI) Quality of Life instrument (QoLI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Kaposi's Sarcoma</condition>
  <condition>HIV+</condition>
  <condition>HIV Positive</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>aldoxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldoxorubicin</intervention_name>
    <arm_group_label>aldoxorubicin</arm_group_label>
    <other_name>INNO-206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years of age; male or female.

          2. HIV (confirmed by ELISA and western blot) with histologically confirmed KS.

          3. Willing to undergo serial tumor biopsies.

          4. Capable of providing informed consent and complying with trial procedures.

          5. KPS ≥70 (Appendix B)

          6. Easter Cooperative Oncology Group (ECOG) PS 0-2.

          7. Life expectancy ≥ 8 weeks.

          8. Measurable (at accessible site or radiographic) tumor lesions according to ACTG TIS
             criteria.

          9. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study. (Adequate contraception includes: oral contraception, implanted
             contraception, intrauterine device implanted for at least 3 months, or barrier method
             in conjunction with spermicide.)

         10. Women of child bearing potential must have a negative serum or urine pregnancy test at
             the Screening Visit and be non-lactating.

         11. Geographic accessibility to the site.

        Exclusion Criteria:

          1. Prior exposure to an anthracycline.

          2. Surgery and/or radiation treatment &lt; 4 weeks prior to Randomization.

          3. Exposure to any investigational agent within 30 days of Randomization.

          4. History of other malignancies (except cured basal cell carcinoma, superficial bladder
             cancer or carcinoma in situ of the cervix) unless documented free of cancer for ≥3
             years.

          5. Laboratory values: Screening serum creatinine &gt;1.5 × upper limit of normal (ULN),
             alanine aminotransferase (ALT) &gt; 2.5 × ULN, total bilirubin &gt;1.5 × ULN, absolute
             neutrophil count (ANC) &lt;1,500/mm3, platelet concentration &lt;75,000/mm3, absolute
             lymphocyte count &lt;1000/mm3, hematocrit level &lt;25% for females or &lt;27% for males, serum
             albumin ≤2.5 g/dL.

          6. Evidence of central nervous system (CNS) hemorrhage National Cancer Institute Common
             Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (published 28 May
             2009) grade 2 or greater on baseline MRI.

          7. Clinically evident congestive heart failure (CHF) &gt; class II of the New York Heart
             Association (NYHA) guidelines.

          8. Current, serious, clinically significant cardiac arrhythmias, defined as the existence
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

          9. History or signs of active coronary artery disease with or without angina pectoris.

         10. Serious myocardial dysfunction defined as ultrasound-determined absolute left
             ventricular ejection fraction (LVEF) &lt;45% of predicted institutional normal value.

         11. Active, clinically significant serious infection requiring treatment with
             antibacterial, antiviral (other than antiretroviral therapy), or antifungal therapy.

         12. Major surgery within 4 weeks prior to Randomization.

         13. Any condition that might interfere with the subject's participation in the study or in
             the evaluation of the study results.

         14. Any condition that is unstable and could jeopardize the subject's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV +</keyword>
  <keyword>HIV positive</keyword>
  <keyword>AIDS</keyword>
  <keyword>Kaposi's sarcoma</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>tumor</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

